Israel-based developer of robotic technology and products, Mazor Robotics Ltd. , recently announced a three-system order for the Mazor X from a leading mid-Atlantic health care organization. Mazor X is a precise surgical assurance platform for spine surgeries.
A glimpse at the stock price movement reveals a solid trend as Mazor Robotics gained almost 24.5% over the last six months, compared with the Zacks categorized Medical Instruments sub-industry’s gain of roughly 0.2% and the S&P 500’s return of 9.1%.
Since the news release, Varian Medical's shares gained 3.4% to close at $22.61 on Dec 23. Meanwhile, a total volume of 83.4 thousand Mazor shares exchanged hands year to date.
Notably, the estimate revision trend for the current year seems unfavorable at the moment, with two estimates moving down in the last two months and no upward movement. Notably, the current year estimate for the stock edged down by 3 cents to a loss of 82 cents per share over the past one month.
Getting back to the development, the latest order in the Mazor X platform is the second in the fourth quarter. Earlier this year, the company won orders in the platform from a major U.S. regional institution in the Northeastern United States. In this regard, the total number of system orders in the fourth quarter will be announced by the company on Jan 5, 2017.
The company’s fundamentals are strong with revenues growing at a CAGR of 5.7% over the past three years. Additionally, a projected sales growth for the current year is 32.1%, compared with industry’s 6.4%, which boosts our confidence on the stock.
Our Take
In Jul 2016, Mazor Robotics first unveiled the Mazor X, which was commercially launched in the North American Spine Society (NASS) Annual Meeting on Oct 26.
We believe the streak of order wins at the Mazor X platform would significantly boost Mazor Robotics’ growth trajectory, especially in the spinal implants and surgical devices market. A report by the Markets And Markets reveals that the niche market is expected to reach a worth of $17.27 billion by 2021, growing at a CAGR of 5.3%.
Of the notable developments earlier this year, Mazor Robotics announced the receipt of a massive $20 million equity investment from Medtronic, a leading medical device company.
Zacks Rank & Key Picks
Currently, Mazor Robotics has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and IDEXX Laboratories, Inc. (IDXX - Free Report) . Addus HomeCare and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy). Meanwhile, LHC Group carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of 51.2%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 19.3% in the last three months.
IDEXX Laboratories has an expected earnings growth of almost 15%. The company posted a promising year-to-date return of almost 64.4%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Israel-based developer of robotic technology and products, Mazor Robotics Ltd. , recently announced a three-system order for the Mazor X from a leading mid-Atlantic health care organization. Mazor X is a precise surgical assurance platform for spine surgeries.
A glimpse at the stock price movement reveals a solid trend as Mazor Robotics gained almost 24.5% over the last six months, compared with the Zacks categorized Medical Instruments sub-industry’s gain of roughly 0.2% and the S&P 500’s return of 9.1%.
Since the news release, Varian Medical's shares gained 3.4% to close at $22.61 on Dec 23. Meanwhile, a total volume of 83.4 thousand Mazor shares exchanged hands year to date.
Notably, the estimate revision trend for the current year seems unfavorable at the moment, with two estimates moving down in the last two months and no upward movement. Notably, the current year estimate for the stock edged down by 3 cents to a loss of 82 cents per share over the past one month.
Getting back to the development, the latest order in the Mazor X platform is the second in the fourth quarter. Earlier this year, the company won orders in the platform from a major U.S. regional institution in the Northeastern United States. In this regard, the total number of system orders in the fourth quarter will be announced by the company on Jan 5, 2017.
The company’s fundamentals are strong with revenues growing at a CAGR of 5.7% over the past three years. Additionally, a projected sales growth for the current year is 32.1%, compared with industry’s 6.4%, which boosts our confidence on the stock.
Our Take
In Jul 2016, Mazor Robotics first unveiled the Mazor X, which was commercially launched in the North American Spine Society (NASS) Annual Meeting on Oct 26.
We believe the streak of order wins at the Mazor X platform would significantly boost Mazor Robotics’ growth trajectory, especially in the spinal implants and surgical devices market. A report by the Markets And Markets reveals that the niche market is expected to reach a worth of $17.27 billion by 2021, growing at a CAGR of 5.3%.
Of the notable developments earlier this year, Mazor Robotics announced the receipt of a massive $20 million equity investment from Medtronic, a leading medical device company.
Zacks Rank & Key Picks
Currently, Mazor Robotics has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and IDEXX Laboratories, Inc. (IDXX - Free Report) . Addus HomeCare and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy). Meanwhile, LHC Group carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of 51.2%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 19.3% in the last three months.
IDEXX Laboratories has an expected earnings growth of almost 15%. The company posted a promising year-to-date return of almost 64.4%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on IDXX - FREE
Get the latest research report on ADUS - FREE